IceCure Medical summarizes the achievements of 2020 and addresses a letter to shareholders

Caesarea March 1, 2021 –  IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that ablates tumors by freezing without the need for surgery, announced today that it issued a letter to shareholders highlighting the company’s achievements in 2020 and the plan for 2021. The letter from Eyal Shamir, CEO of IceCure, appears under the read more links in full in English and Hebrew. 

Read more (English)….

Read more (Hebrew)…